Nautilus launches Early Access Program for novel proteomics platform

Nautilus Biotechnology (NAUT) announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoforms assay as its first offering. The program makes Nautilus’ Iterative Mapping approach to measuring proteins and their variants available to an exclusive group of researchers. “Through years of validation, we’ve shown that our platform delivers reproducible, high-quality proteomic data with a level of resolution and scale that differentiates it from other approaches. These capabilities give us the confidence to launch the Early Access Program, knowing our customers will be set up for success from the outset,” said Sujal Patel, co-founder and CEO of Nautilus. “We are thrilled to first offer our proprietary tau proteoforms assay, which several of our partners at world-class research institutions are already harnessing for breakthrough Alzheimer’s research, to kick off this new era for proteomics.”